Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97291 | 0.83 | CA1 (0.41) | MAPTL3MBTL1KDM4EALDH1A1POLB | |
| SCHEMBL3315142 | 0.81 | MAOB (0.36) | MAPTHPGDMAPK1L3MBTL1KDM4E | |
| SCHEMBL6483235 | 0.79 | MAPT (0.40) | MAPTKDM4EALDH1A1TDP1KMT2A | |
| SCHEMBL5251072 | 0.75 | KMT2A (0.52) | MAPTHPGDL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL1269005 | 0.74 | CYP3A4 (0.33) | MAPTMAPK1POLBHTTALOX15 | |
| SCHEMBL10068105 | 0.74 | MAPT (0.47) | MAPTHPGDMAPK1L3MBTL1KDM4E | |
| SCHEMBL6210588 | 0.73 | HTT (0.45) | MAPTHPGDMAPK1L3MBTL1KDM4E | |
| SCHEMBL17087123 | 0.71 | MAPT (0.53) | MAPTHPGDMAPK1L3MBTL1KDM4E | |
| SCHEMBL2799797 | 0.71 | MAPT (0.53) | MAPTHPGDMAPK1L3MBTL1KDM4E | |
| SCHEMBL113262 | 0.71 | KMT2A (0.61) | HPGDKDM4EALDH1A1HTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5837873-A | PROTECTED OXYDIAMINES | ABBOTT LABORATORIES (US) | 1998-11-17 | — | — | US | claimed |
| US-8470829-B2 | Imidazolidine derivative and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-06-25 | — | — | US | disclosed |
| US-8314071-B2 | Bioactive molecules from co-cultivation of microbes | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110306615-A1 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-12-15 | — | — | US | disclosed |
| US-8026383-B2 | Process for the preparation of intermediates useful in the synthesis of statin derivatives | BASF SE (DE) | 2011-09-27 | — | — | US | disclosed |
| US-20110046411-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES | CIBA SPECIALTY CHEMICALS CORPORATION | 2011-02-24 | — | — | US | disclosed |
| US-7855302-B2 | Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino-3.5-dihydroxyhepanoic acid derivatives and intermediates thereof | CIBA SPECIALTY CHEMICALS CORP. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100249051-A1 | Bioactive Molecules from Co-Cultivation of Microbes | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-09-30 | — | — | US | disclosed |
| US-7692034-B2 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-04-06 | — | — | US | disclosed |
| EP-2161250-A1 | Process for the preparatiom of 7-amino-syn-3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | BASF SE (DE) | 2010-03-10 | — | — | EP | disclosed |
| EP-1404639-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES ESPECIALLY 7-AMINO 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, AND INTERMEDIATES THEREOF | Ciba SC Holding AG (CH) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003044011-A1 | PYRROLE SYNTHESIS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-05-30 | — | — | WO | disclosed |
| WO-2003004456-A1 | PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES VIA 6-CYANO SYN 3,5-DIHYDROXY HEXANOIC ACID DERIVATIVES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-01-16 | — | — | WO | disclosed |
| WO-2003004455-A2 | PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, INTERMEDIATES THEREOF AND METHODS FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-01-16 | — | — | WO | disclosed |
| WO-2003004450-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES ESPECIALLY 7-AMINO 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, AND INTERMEDIATES THEREOF | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-01-16 | — | — | WO | disclosed |
| US-5837873-A | PROTECTED OXYDIAMINES | ABBOTT LABORATORIES (US) | 1998-11-17 | — | — | US | disclosed |
| EP-0421441-B1 | Pantothenic acid derivatives | FUJIREBIO KK (JP) | 1995-01-25 | — | — | EP | disclosed |
| EP-0633242-A1 | Heptanoate derivatives | FUJIREBIO Inc. (JP) | 1995-01-11 | — | — | EP | disclosed |
| US-5120738-A | Cardiovascular disorders | FUJIREBIO INC. (JP) | 1992-06-09 | — | — | US | disclosed |
| EP-0421441-A2 | Pantothenic acid derivatives | FUJIREBIO INC. (JP) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046411-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES | HMGCR, SREBF1, LCAT | MAPT 4324/4885HPGD 2434/4885MAPK1 2254/4885 |
| US-20110306615-A1 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | CBR1, NR0B1, CNKSR1 | MAPT 4811/4885HPGD 2807/4885MAPK1 2046/4885 |
| US-20100249051-A1 | Bioactive Molecules from Co-Cultivation of Microbes | BMP4, BMP2, LSS | MAPT 2872/4885HPGD 491/4885MAPK1 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.